A catheter and associated positioning system can include sensors and software to ascertain the extent of expansion of an expandable distal member of the catheter. Sensors on the distal member can be configured so that the system is able to determine a longitudinal dimension and a radial dimension of the distal-end assembly and determine extent of expansion of the distal member based on those metrics. At least the longitudinal dimension can be derived from advanced current localization (ACL) techniques utilizing an electrode at a distal end of the expandable distal member.

Device, systems, and methods for cryoablation are described herein. In some implementations, the devices and systems are used to for cryoneurolysis or cryoablation of nerves. An example cryoablation probe includes a tubular member having a proximal end and a distal end. The tubular member has a probe tip arranged at the distal end. The probe also includes one or more energy elements arranged along an axial direction of the tubular member, and one or more sensor elements arranged along the axial direction of the tubular member.

The present invention relates to a treatment apparatus and a method of controlling the same, and provides a treatment apparatus including an insertion unit formed in such a way as to be inserted into a tissue through a tissue surface, a bending sensing unit sensing bending of the insertion unit occurring during insertion, and a controller controlling the insertion operation of the insertion unit based on information sensed by the bending sensing unit, and a method of controlling the same. In accordance with the present invention, there is an advantage in that a treatment effect can be improved because treatment can be performed in the state in which the insertion unit has been inserted into an accurate target location.

The present invention is directed toward a device that performs ablation of tissue. The device has a catheter with a shaft through which an ablative agent can travel, a first positioning element attached to the catheter shaft at a first position and a second positioning element attached to the catheter shaft at a second position. The shaft also has ports through which the ablative agent can be released.

A medical instrument is provided and includes a housing and a shaft coupled to the housing. The shaft has a proximal end and a distal end. An end-effector assembly is disposed at the distal end of the shaft. The end-effector assembly includes first and second jaw members. At least one of the first and second jaw members is movable from a first position wherein the first and second jaw members are disposed in spaced relation relative to one another to at least a second position closer to one another wherein the first and second jaw members cooperate to grasp tissue therebetween. The medical instrument also includes one or more light-emitting elements and one or more light-detecting elements configured to generate one or more signals indicative of tissue florescence. The one or more light-emitting elements are adapted to deliver light energy to tissue grasped between the first and second jaw members.

A medical device may include an ablation device configured to deliver ablation energy to a treatment site. The medical device may further include a probe device configured to deliver excitation radiation to the treatment site. Further the medical device may include a radiation-receiving device configured to receive photoluminescence radiation emitted from the treatment site in response to the treatment site being illuminated by the excitation radiation and to generate a detection signal in response to the received photoluminescence radiation. Additionally, the excitation radiation may be different from the ablation energy.

Systems and methods for assessing sympathetic nervous system (SNS) tone for renal neuromodulation therapy are disclosed herein. A system configured in accordance with embodiments of the present technology can include, for example, a detector attached to or implanted in a patient and a receiver communicatively coupled to the detector. The detector can measure cardiac data and the receiver and/or a device communicatively coupled thereto can analyze the cardiac data to provide one or more SNS tone indicators. The SNS tone indicators can be used to determine whether a patient will be responsive to a neuromodulation therapy and/or whether a neuromodulation therapy was effective.

A catheter system (100) for placement within a blood vessel (108) having a vessel wall (108A) for treating a treatment site (106) within or adjacent to the vessel wall (108A) within a body (107) of a patient (109) includes a system console (123), one or more energy guides (122A), and an optical connector assembly (251). The system console (123) includes an energy source (124) and a console connection aperture (148). The one or more energy guides (122A) are configured to receive energy from the energy source (124). The optical connector assembly (251) includes a guide coupling housing (250) that retains at least a portion of each of the one or more energy guides (122A). The guide coupling housing (250) is configured to be mechanically connected to the system console (123) with at least a portion of the guide coupling housing (250) being configured to fit and be selectively retained within the console connection aperture (148) so that the one or more energy guides (122A) are adjustably and more precisely aligned within the guide coupling housing (250) and relative to the energy from the energy source (124) to receive the energy from the energy source (124).

Methods for estimating of the effectiveness of catheter ablation procedures to form lesions, and particular lesions which together form an ablation segment of an ablation line. Lesion effectiveness parameters are received, and effectiveness, optionally the joint effectiveness, of corresponding ablations (optionally planned, current, and/or already performed) is estimated. In some embodiments, estimating is based on use by computer circuitry of an estimator constructed based on observed associations between previously analyzed lesion effectiveness parameters, and observed lesion effectiveness. Additionally or alternatively, estimators may be constructed based on analytic functions. The estimator is used by application to the received lesion effectiveness parameters.

Systems and methods are configured to detect and/or ablate cancerous tissue, such as during surgery. The system uses Laser Ramen Spectroscopy (LRS) or Surface Enhanced Raman Spectroscopy (SERS) to enhance a detection signal pursuant to a spectroscopy analysis of tissue. Rapid in situ detection of cancer can be combined with immediate laser thermal ablation of the cancerous tissue. The detection and ablation can occur before, during, or after surgical resection.